Pathology consultation on warfarin pharmacogenetic testing

American Journal of Clinical Pathology

Volumn 135, Issue 1, 2011, Pages 13-19

  Stack, Gary ^a,b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CYP2C9; Genotype; Pharmacogenetics; VKORC1; Warfarin

Indexed keywords

WARFARIN;

CONSULTATION; DNA POLYMORPHISM; DOSE RESPONSE; FOOD AND DRUG ADMINISTRATION; GENE DOSAGE; GENOTYPE; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; DRUG TOXICITY; GENETIC TESTING; GENOTYPE; HEMORRHAGE; HUMANS; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; POLYMORPHISM, GENETIC; WARFARIN;

EID: 79251489782     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPAO82OTNPUBLW     Document Type: Review

References (43)

1. Coumadin tablets; Coumadin for injection [package insert]. Princeton, NJ: Bristol-Myers-Squibb; 2010.
2. Landefeld CS, Beyth RJ. Anticoagulant bleeding: clinical epidemiology, prediction, and prevention. Am J Med. 1993;95:315-328.
3. Kamali F, Wynne H. Pharmacogenetics of warfarin. Annu Rev Med. 2010;61:63-75.
4. Moyer TP, O'Kane DJ, Baudhuin LM, et al. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc. 2009;84:1079-1094.
5. Cooper GM, Johnson JA, Langaee TY, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood. 2008;112:1022-1027.
6. Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009;5:e1000433. doi:10.1371/journal.pgen.1000433.
7. Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007;116:2563-2570.
8. Wadelius M, Chen LY, Downes K, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 2005;5:262-270.
9. Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required warfarin dose. Blood. 2008;111:4106-4112.
10. Pautas E, Moreau C, Gouin-Thibault I, et al. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharmacol Ther. 2010;87:57-64.
11. Voora D, Koboldt DC, King CR, et al. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther. 2010;87:445-451.
12. King CR, Porche-Sorbet RM, Gage BF, et al. Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose. Am J Clin Pathol. 2008;129:876-883.
13. Langley MR, Booker JK, Evans JP, et al. Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms. J Mol Diagn. 2009;11:216-224.
14. Babic N, Haverfield EV, Burrus JA, et al. Comparison of performance of three commercial platforms for warfarin sensitivity genotyping. Clin Chim Acta. 2009;406:143-147.
15. Maurice CB, Barua PK, Simses D, et al. Comparison of assay systems for warfarin-related CYP2C9 and VKORC1 genotyping. Clin Chim Acta. 2010;411:947-954.
16. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphisms and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106:2329-2333.
17. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84:326-331.
18. The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360:753-764.
19. Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood. 2009;113:784-792.
20. Zhu Y, Shennan M, Reynolds KK, et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin Chem. 2007;53:1199-1205.
21. Schelleman H, Chen J, Chen Z, et al. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. Clin Pharmacol Ther. 2008;84:332-339.
22. Wu AHB, Wang P, Smith A, et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics. 2008;9:169-178. (Pubitemid 351566941)
23. Online warfarin dosing. http://www.WarfarinDosing.org. Accessed May 21, 2010.
24. Roper N, Storer B, Bona R, et al. Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing. J Mol Diagn. 2010;12:283-291.
25. Crowther MA, Ginsberg JB, Kearon C, et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med. 1999;159:46-48. (Pubitemid 29044118)
26. Kovacs MJ, Rodger M, Anderson DR, et al. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. Ann Intern Med. 2003;138:714-719.
27. Hillman MA, Wilke RA, Yale SH, et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res. 2005;3:137-145.
28. Lenzini PA, Grice GR, Milligan PE, et al. Laboratory and clinical outcomes of pharmacogenetic vs clinical protocols for warfarin initiation in orthopedic patients. J Thromb Haemost. 2008;6:1655-1662.
29. Lenzini P, Wadelius M, Kimmel S, et al. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther. 2010;87:572-578.
30. Lesko LJ. The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics. Clin Pharmacol Ther. 2008;84:301-303.
31. Garcia DA. Warfarin and pharmacogenomic testing: the case for restraint. Clin Pharmacol Ther. 2008;84:303-305.
32. Wadelius M. Point: use of pharmacogenetics in guiding treatment with warfarin. Clin Chem. 2009;55:709-711.
33. Eby CS. Counterpoint: pharmacogenetic-based initial dosing of warfarin: not ready for prime time. Clin Chem. 2009;55:712-714.
34. Rosove MH, Grody WW. Should we be applying warfarin pharmacogenetics to clinical practice? no, not now. Ann Intern Med. 2009;151:270-273, W95.
35. Teagarden JR. Warfarin and pharmacogenomic testing: what would Pascal do [editorial]? Pharmacotherapy. 2009;29:245-247.
36. Shurin SB, Nabel EG. Pharmacogenomics: ready for prime time [editorial]? N Engl J Med. 2008;358:1061-1063. (Pubitemid 351347106)
37. Wu AHB. Pharmacogenomic testing for warfarin: we are ready now [editorial]. Expert Rev Cardiovasc Ther. 2009;7:1483-1485.
38. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther. 2008;83:460-470. (Pubitemid 351272635)
39. Huang S-W, Chen H-S, Wang X-Q, et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics. 2009;19:226-234.
40. Epstein RS, Moyer TP, Aubert RE, et al. Warfarin genotyping reduces hospitalization rates: results from the MM-WES (Medco-Mayo Warfarin Effectiveness Study). J Am Coll Cardiol. 2010;55:2804-2812.
41. Valdes R Jr, Payne D, Linder MW, eds. Laboratory Medicine Practice Guidelines: Laboratory Analysis and Application of Pharmacogenetics to Clinical Practice. Washington, DC: National Academy of Clinical Biochemistry; 2010. http://www.aacc.org/members/nacb/LMPG/OnlineGuide/PublishedGuidelines/LAACP/ Documents/PGx-Guidelines.pdf. Accessed May 14, 2010.
42. Flockhart DA, O'Kane D, Williams MS, et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin [American College of Medical Genetics policy statement]. Genet Med. 2008;10:139-150.
43. Cavallari LH, Langaee TY, Momary KM, et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther. 2010;87:459-464.